Pays: Pays-Bas
Langue: anglais
Source: HMA (Heads of Medicines Agencies)
marbofloxacin 20 mg
CP Pharma Handelsgesellschaft mbH
QJ01MA93
Tablet
marbofloxacin
Cats, Dogs
2012-12-21
Issued: March 2013 AN: 01688/2011 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbotab P 20 mg tablets for dogs and cats List of agreed names in the Member States where product is authorized. Italy, Germany, France, The Netherlands, Belgium, Hungary Marbotab P 20 mg tablets for dogs and cats Denmark Marbotab P, 20 mg tablets, for dogs and cats United Kingdom, Ireland, Poland, Spain, Austria Marbotab 20 mg tablets for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Marbofloxacin 20 mg EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Beige tablets with white speckled, cross-snap-tab. The tablets can be divided into quarters. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs, cats 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of infections caused by strains of microorganisms susceptible to marbofloxacin. IN DOGS: Skin and soft tissue infections (skinfold pyoderma, impetigo, folli culitis, furunculosis, cellulitis); Urinary tract infections (UTI) associated or not with prostatitis; Respiratory tract infections. Issued: March 2013 AN: 01688/2011 Page 2 of 6 IN CATS: Skin and soft tissue infections (wounds, abscesses, phlegmons); Upper respiratory tract infections. See section 5.1, Pharmacodynamic properties for further information on specific target pathogens. 4.3 CONTRAINDICATIONS Marbofloxacin should not be Lire le document complet